Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis

Blood

Volumn 124, Issue 16, 2014, Pages 2498-2506

  Reece, Donna E ^a   Hegenbart, Ute ^b   Sanchorawala, Vaishali ^c   Merlini, Giampaolo ^d   Palladini, Giovanni ^d   Bladé, Joan ^e   Fermand, Jean Paul ^f   Hassoun, Hani ^g   Heffner, Leonard ^h   Kukreti, Vishal ^a   Vescio, Robert A ⁱ   Pei, Lixia ^j   Enny, Christopher ^j   Esseltine, Dixie Lee ^k   Van De Velde, Helgi ^l   Cakana, Andrew ^l   Comenzo, Raymond L ^m  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF PAVIA   (Italy)

^e UNIVERSITY OF BARCELONA   (Spain)

^f SAINT LOUIS HOSPITAL   (France)

^g MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^h EMORY UNIVERSITY   (United States)

ⁱ CEDARS SINAI MEDICAL CENTER   (United States)

^j LLC   (United States)

^k TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

^l JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^m TUFTS MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID PROTEIN; BENDAMUSTINE; BORTEZOMIB; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN LAMBDA CHAIN; LENALIDOMIDE; MELPHALAN; NEW DRUG; PREDNISONE; THALIDOMIDE; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; PYRAZINE DERIVATIVE;

ADULT; AMYLOID LONG CHAIN AMYLOIDOSIS; AMYLOIDOSIS; ARTICLE; CAUSE OF DEATH; DISEASE COURSE; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG RESPONSE; DRUG SAFETY; FEMALE; FOLLOW UP; HEMATOLOGIC DISEASE; HUMAN; LIGHT CHAIN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; RELAPSE; STEM CELL TRANSPLANTATION; TREATMENT DURATION; TREATMENT PLANNING; AGED; CLINICAL TRIAL; MIDDLE AGED; RECURRENT DISEASE; SURVIVAL; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; AMYLOIDOSIS; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PYRAZINES; RECURRENCE; SURVIVAL ANALYSIS;

EID: 84908144097     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-04-568329     Document Type: Article

References (50)

1. Comenzo RL. Managing systemic light-chain amyloidosis. J Natl Compr Canc Netw. 2007;5(2):179-187.
2. Desport E, Bridoux F, Sirac C, et al. Al amyloidosis. Orphanet J Rare Dis. 2012;7(Aug 21):54.
3. Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. N Engl J Med. 1997;337(13):898-909.
4. Sitia R, Palladini G, Merlini G. Bortezomib in the treatment of AL amyloidosis: targeted therapy? Haematologica. 2007;92(10):1302-1307.
5. Lamm W, Willenbacher W, Lang A, et al. Efficacy of the combination of bortezomib and dexamethasone in systemic AL amyloidosis. Ann Hematol. 2011;90(2):201-206.
6. Gertz MA, Lacy MQ, Dispenzieri A, et al. Effect of hematologic response on outcome of patients undergoing transplantation for primary amyloidosis: importance of achieving a complete response. Haematologica. 2007;92(10):1415-1418.
7. Palladini G, Russo P, Nuvolone M, et al. Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis. Blood. 2007;110(2):787-788.
8. Sanchorawala V, Skinner M, Quillen K, Finn KT, Doros G, Seldin DC. Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation. Blood. 2007;110(10):3561-3563.
9. Suzuki K. Diagnosis and treatment of multiple myeloma and AL amyloidosis with focus on improvement of renal lesion. Clin Exp Nephrol. 2012;16(5):659-671.
10. Gertz MA, Lacy MQ, Dispenzieri A, et al. Autologous stem cell transplant for immunoglobulin light chain amyloidosis: a status report. Leuk Lymphoma. 2010;51(12):2181-2187.
11. Rosenzweig M, Landau H. Light chain (AL) amyloidosis: update on diagnosis and management. J Hematol Oncol. 2011;4(Nov 18):47.
12. Sanchorawala V. Light-chain (AL) amyloidosis: diagnosis and treatment. Clin J Am Soc Nephrol. 2006;1(6):1331-1341.
13. Millennium Pharmaceuticals Inc. VELCADE® Prescribing Information. October 2012 (Revision 15).
14. Chari A, Barley K, Jagannath S, Osman K. Safety and efficacy of triplet regimens in newly diagnosed light chain amyloidosis. Clin Lymphoma Myeloma Leuk. 2013;13(1):55-61.
15. Mikhael JR, Schuster SR, Jimenez-Zepeda VH, et al. Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood. 2012;119(19):4391-4394.
16. Venner CP, Lane T, Foard D, et al. Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. Blood. 2012;119(19):4387-4390.
17. Wechalekar AD, Lachmann HJ, Offer M, Hawkins PN, Gillmore JD. Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease. Haematologica. 2008;93(2):295-298.
18. Shah GL, Kaul E, Fallo S, et al. Subcutaneous bortezomib in combination regimens in newly diagnosed patients with myeloma or systemic AL amyloidosis: high response rates and minimal toxicity. Blood. 2012;120(21):Abstract 2968.
19. Kastritis E, Anagnostopoulos A, Roussou M, et al. Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone. Haematologica. 2007;92(10):1351-1358.
20. Kastritis E, Wechalekar AD, Dimopoulos MA, et al. Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. J Clin Oncol. 2010;28(6):1031-1037.
21. Palladini G, Foli A, Russo P, et al. Treatment of IgM-associated AL amyloidosis with the combination of rituximab, bortezomib, and dexamethasone. Clin Lymphoma Myeloma Leuk. 2011;11(1):143-145.
22. Zhai YP, Liu HN, Yu YP, et al. [Treatment of primary systemic amyloidosis with the combination of bortezomib and dexamethasone]. Zhonghua Xue Ye Xue Za Zhi. 2010;31(5):319-322.
23. Reece DE, Sanchorawala V, Hegenbart U, et al; VELCADE CAN2007 Study Group. Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study. Blood. 2009;114(8):1489-1497.
24. Dubrey SW, Reece DE, Sanchorawala V, et al; Velcade Can2007 Study Group. Bortezomib in a phase 1 trial for patients with relapsed AL amyloidosis: cardiac responses and overall effects. QJM. 2011;104(11):957-970.
25. Reece DE, Hegenbart U, Sanchorawala V, et al. Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study. Blood. 2011;118(4):865-873.
26. Gertz MA, Comenzo R, Falk RH, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol. 2005;79(4):319-328.
27. Kumar S, Dispenzieri A, Lacy MQ, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 2012;30(9):989-995.
28. Mollee P, Tate J, Pretorius CJ. Evaluation of the N Latex free light chain assay in the diagnosis and monitoring of AL amyloidosis. Clin Chem Lab Med. 2013;51(12):2303-2310.
29. Palladini G, Dispenzieri A, Gertz MA, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol. 2012;30(36):4541-4549.
30. Wechalekar AD, Goodman HJ, Lachmann HJ, Offer M, Hawkins PN, Gillmore JD. Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood. 2007;109(2):457-464.
31. Palladini G, Russo P, Milani P, et al. A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis. Haematologica. 2013;98(3):433-436.
32. Sanchorawala V, Wright DG, Rosenzweig M, et al. Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial. Blood. 2007;109(2):492-496.
33. Dhodapkar MV, Hussein MA, Rasmussen E, et al; United States Intergroup Trial Southwest Oncology Group. Clinical efficacy of high-dose dexamethasone with maintenance dexamethasone/alpha interferon in patients with primary systemic amyloidosis: results of United States Intergroup Trial Southwest Oncology Group (SWOG) S9628. Blood. 2004;104(12):3520-3526.
34. Kyle RA, Gertz MA, Greipp PR, et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med. 1997;336(17):1202-1207.
35. Skinner M, Anderson J, Simms R, et al. Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only. Am J Med. 1996;100(3):290-298.
36. Palladini G, Anesi E, Perfetti V, et al. A modified high-dose dexamethasone regimen for primary systemic (AL) amyloidosis. Br J Haematol. 2001;113(4):1044-1046.
37. Dispenzieri A, Lacy MQ, Katzmann JA, et al. Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood. 2006;107(8):3378-3383.
38. Lachmann HJ, Gallimore R, Gillmore JD, et al. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol. 2003;122(1):78-84.
39. Kumar SK, Dispenzieri A, Lacy MQ, et al. Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis. Am J Hematol. 2011;86(3):251-255.
40. Kumar S, Dispenzieri A, Katzmann JA, et al. Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features. Blood. 2010;116(24):5126-5129.
41. Raval GG, Gertz MA, Lacy MQ, et al. Survival after second, third, and fourth line therapy better than expected in patients with previously treated AL amyloidosis who were not transplant candidates at diagnosis. Blood. 2012;120(21):Abstract 946.
42. Gasparetto C, Sanchorawala V, Synder RM, et al. Use of melphalan/dexamethasone/bortezomib in AL amyloidosis. J Clin Oncol. 2010;28(Suppl 15): Abstract 8024.
43. Arnaud J, Mohty D, Desport E, Bridoux F. Actualites dans le traitement de l'amylose AL. Hematologie. 2012;18(2):116-123.
44. Minnema M, Hazenberg B, Croockewit A, et al. De behandeling van AL-amyloidose in Nederland anno 2013. Ned Tijdschr Hematol. 2013;10(5):165-179.
45. Richardson PG, Sonneveld P, Schuster MW, et al; Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352(24):2487-2498.
46. Berenson JR, Jagannath S, Barlogie B, et al. Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma. Cancer. 2005;104(10):2141-2148.
47. Orlowski RZ, Nagler A, Sonneveld P, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol. 2007;25(25):3892-3901.
48. Bringhen S, Larocca A, Rossi D, et al. Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood. 2010;116(23):4745-4753.
49. Reeder CB, Reece DE, Kukreti V, et al. Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma. Blood. 2010;115(16):3416-3417.
50. de Vos S, Goy A, Dakhil SR, et al. Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma. J Clin Oncol. 2009;27(30):5023-5030.